师资队伍

师资队伍
教师名录

杜子秀

副研究员

 

电话:021-34204739
邮箱:zixiudu@sjtu.edu.cn

人才奖励 上海市人才发展计划;晨星青年学者
E-mail zixiudu@sjtu.edu.cn
办公室电话 021-34204739
办公室地址 生物药学大楼6号楼412房间

教育科研经历

2003/09–2007/06, 浙江大学, 高分子化学与物理, 博士
2011/01-至今,上海交通大学,药学院,副研究员
2012/04-2013/4,英国伦敦大学学院(UCL),分子免疫学研究所,博士后
2009/09-2010/12,上海交通大学,药学院,助理研究员
2007/09-2009/08,上海交通大学,博士后,合作导师:金拓

主持或参加科研项目(课题):
1. 自然科学基金面上项目,82073802,赫赛汀、多肽和siRNA协同治疗复发性乳腺癌的双靶向复合纳米凝胶的构建及评价,2021/01-2024/12,56万元,在研,主持。
2. 上海市人才发展计划资金,2017111,生物可降解抗HER2单抗/PEG/PCL/紫杉醇纳米输送靶向治疗HER2阳性乳腺癌的研究,2017/09-2019/12,20万,在研,主持。
3. 自然科学基金重大项目,81690262,高效递释系统对生物大分子药物结构与活性的影响规律,2017/01-2021/12,241.4万元,在研,第二参加人。
4. 闵行产学研项目,2011MH093,以体内天然存在的单体合成和构建可降解聚阳离子基因载体,2011/06-2013/10,12万元,已结题,主持(作为高校方)。
5. 闵行产学研项目,2013MH146,利用可降解亚胺类聚阳离子/核酸纳米颗粒与醋酸氢化可的松形成药用混悬注射液,2013/06-2015/10,21万元,已结题,主持(作为高校方)。
6.闵行产学研项目,2013MH146,生物可降解抗HER2单抗和促凋亡survivin siRNA联合靶向治疗HER2阳性乳腺癌制剂,2016/06-2018/10,21万元,在研,主持(作为高校方)。
7. 十二五国家新药创制专项,2011ZX09501-001-05,新型药物制剂和辅料的临床前研究,2010/01-2014/12,571.83万元,已结题、参加。
8. 国家自然科学基金青年项目,30901881,以精胺为基本构建单元并可降解为精胺的聚阳离子基因载体,2010/01-2012/12,20万元,已结题,主持。
9. 上海市科委纳米专项,1052nm03900,人体内源性分子构建的类病毒合成基因载体,2010/06-2012/06,50万元,已结题,参加。
10. 十一五国家新药创制专项,2009ZX09310-007、针对生物技术药物的相关给药技术平台、2008/01-2010/11、参与。
11.全国博士后特别资助基金,200801198、以体内天然存在的单体合成和构建可降解聚阳离子基因载体、2008/07-2009/08、主持。
12.上海市2008年博士后面上项目(A类),08R214128、聚阳离子非病毒基因物质输送载体的合理化设计与构建、2008/01-2009/08、主持。
13.第四十二批中国博士后科学基金一等资助金,20070420103、聚阳离子非病毒基因物质输送载体的合理化设计与构建、2007/09-2009/08、主持。
生物材料δ药物输送。(1)专注于抗体、核酸、多肽和化疗药物联合抗癌纳米制剂和功能化水凝胶的研发;(2)其它药物纳米输送体系的构建。
代表性期刊论文

(1) Huiling Song#, Haosheng Li#, Xiaonan Shen, Kuai Liu, Haoran Feng, Jiahua Cui, Wei Wei, Xiaolu Sun, Qiong Fan, Wei Bao, Haiyan Zhou, Liheng Qian, Huizhen Nie, Xi Cheng*, Zixiu Du*, A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma. Acta Biomater 2024, 177, 456-471.

(2) Juan Chen#, Jinjin Li#, Xiaolu Sun#, Huixia Lu, Kuai Liu, Zhenbo Li, Jianyue Guan, Huiling Song, Wei Wei, Yanhong Ge, Qiong Fan, Wei Bao, Buyong Ma*, Zixiu Du*, Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with A HER2/CD44-targeted Hydrogel Nanobot, Small, 2023, 2301043.

(3) Xiaolu Sun, Kuai Liu, Shuli Lu, Weina He*, Zixiu Du *, Targeted therapy and immunotherapy for heterogeneous breast cancer, Cancers, 2022, 14, 5456, 1-23. (IF= 6.57)

(4) Huiling Song, Stephen L. Hart, Zixiu Du*, Assembly strategy of liposome and polymer systems for siRNA delivery, Int. J. Pharm, 2021, 592(5): 120033. (IF= 5.89)

(5) Yao Liu†, Yuanzhen Liu†, Zixiu Du†, Lidan Zhang, Juan Chen, Zhen Shen, Qian Liu, Juanxiu Qin, Huiying Lv, Hua Wang1, Lei He, Junlan Liu, Qian Huang, Yuhui Sun*, Michael Otto*, Min Li*, Skin microbiota analysis-inspired development of novel anti-infectives, Microbiome, (2020) 8:85. (IF = 14.65)

(6) Jiahui Peng, Juan Chen, Fang Xie, Wei Bao, Hongyan Xu, Hongxia Wang*, Yuhong Xua, Zixiu Du*, Herceptin-conjugated Paclitaxel Loaded PCL-PEG Worm-like Nanocrystal Micelles for the Combinatorial Treatment of HER2-positive Breast Cancer, Biomaterials, 222 (2019) 119420. (IF = 12.48)

(7) Yaoyao Liang, Jiahui Peng, Ning Li, Cynthia Yu-Wai-Man, Qian Wang, Yuhong Xu, Hongxia Wang*, Aristides D Tagalakis, Zixiu Du*, Smart Nanoparticles Assembled by Endogenous Molecules for siRNA Delivery and Cancer Therapy via CD44 and EGFR Dual-targeting, Nanomedicine: Nanotechnology, Biology and Medicine, 2019, 15, 207-215. (IF= 6.458)

(8) Fang Xie, Luchen Zhang, Jinliang Peng, Chong Li, Jun Pu, Yuhong Xu, Zixiu Du*, Hepatic Carcinoma Selective Nucleic Acid Nanovector Assembled by Endogenous Molecules Based on Modular Strategy, Mol. Pharmaceutics 2017, 14, 1841−1851.

(9) Luchen Zhang, Zhenbo Li, Fangli Sun, Yuhong Xu, Zixiu Du*, Effect of Inserted Spacer in Hepatic Cell-penetrating Multifunctional Peptide Component on the DNA Intracellular Delivery of Quaternary Complexes Based on Modular Design, Int. J. Nanomed 2016:11 6283–6295.

(10) Zixiu Du, M M Munye, A D Tagalakis, M D Manunta, S L Hart, The role of the helper lipid on the DNA transfection efficiency of lipopolyplex, Scientific Reports, 2014, 4(2045-2322):1-5.

(11) Zixiu Du, Shengnan Xiang, Yi Zang, Yi Zhou, Chuandong Wang, Hailing Tang, Tuo Jin, Xiaoling Zhang *, Polyspermine imine, a pH responsive polycationic siRNA carrier degradable to endogenous metabolites, Mol. Pharmaceutics, 2014,11(10): 3300-3306.

(12) Zixiu Du, Moying Chen, Qianqian He,Yi Zhou, Tuo Jin, Polymerized spermine as a novel polycationic nucleic acid carrier system, Int. J. Pharm, 2012, 434(1-2): 437-443.

(13) Zixiu Du, JunTing Xu, ZhiQiang Fan, Regulation of micellar morphology of PCL-b-PEO block copolymers by crystallization temperature, Macromolecular Rapid Communications, 2008, 29(6): 467-471.

(14) Zixiu Du, JunTing Xu, Qi Dong, ZhiQiang Fan, Micellar morphologies of
poly(epsilon-caprolactone)-b-poly(ethylene oxide) block copolymers in water with a crystalline core, Macromolecules, 2007, 40(21): 7633-7637.

(15) Zixiu Du, JunTing Xu, Qi Dong, ZhiQiang Fan, Thermal fractionation and effect of comonomer distribution on the crystal structure of ethylene-propylene copolymers, Polymer, 2009, 50(11): 2510-2515.

(16) Zixiu Du, JunTing Xu, Qi Dong, ZhiQiang Fan, Effects of comonomer content, comonomer distribution and crystallization condition on crystallinity and dimension of crystal lattice of ethylene-propylene copolymers, E-Polymers, 2010, 097: 79-85.

(17) Zixiu Du, JunTing Xu, Yong Yang, ZhiQiang Fan, Synthesis and characterization of poly(epsilon-caprolactone)-b-poly(ethylene glycol) block copolymers prepared by a salicylaldimine-aluminum complex, Journal of Applied Polymer Science, 2007, 105(2): 771-776.

(18) Zixiu Du, JunTing Xu, Yong Yang, ZhiQiang Fan, Effect of molecular weight on spherulitic growth rate of poly(epsilon-caprolactone) and poly(epsilon-caprolactone)-b-poly(ethylene glycol), Journal of Applied Polymer Science, 2007, 104(5): 2986-2991.

(19) Zixiu Du, JunTing Xu, Xin Wang Fan, Zhiqiang, Microstructure of ethylene/propylene random copolymers prepared by a fluorinated bis(phenoxy-imine)Ti catalyst, Polymer Bulletin, 2007, 58(5-6): 903-911.

(20) Tagalakis Aristides D, Lee Do Hyang D,Bienemann Alison S, Zhou Haiyan, Munye Mustafa M, Saraiva Luisa, McCarthy David, Du Zixiu, Vink Conrad A, Maeshima Ruhina, White Edward A, Gustafsson Kenth, Hart Stephen L, Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery, Biomaterials, 2014, 35 (29): 8406-8415.
授权发明专利

(1) 杜子秀,金拓,何倩倩,可降解亚胺类聚阳离子及其合成方法、纳米颗粒,2013.8.28-2033.8.27,中国,专利号:CN102532565B。
(2) 杜子秀,金拓,黄立群,可降解为精胺的聚阳离子及其合成方法、纳米颗粒.,2013.11.20-2033.11.19,中国,授权号:CN102516534B。
(3) 杜子秀,金拓,臧怡,段诗悦,可降解酰胺类聚阳离子及其制备方法、纳米颗粒,2014.10.15-2034.10.14,中国,授权号:CN102516178B。
(4) 杜子秀,金拓,吴飞,黄立群,臧怡,可降解亚胺类聚阳离子及其合成方法、纳米颗粒,2014.6.18-2034.6.17,中国,授权号:CN102516535B。
(5) 金拓,杜子秀,由内源性携带氨基的单体形成的聚阳离子基因载体,2013.3.6-2033.3.5,中国,授权号:CN102083972B。
(6) 杜子秀,徐宇虹,黄莹莹,梁瑶瑶,闫克英,一种核酸与化学药物的复合制剂及其制备方法,中国,授权号:CN105031653B。
(7) 杜子秀,徐宇虹,梁瑶瑶*,一种联合输送核酸与多肽的纳米制剂及制备方法,中国,授权号:CN105327358B。
(8) 杜子秀,徐宇虹,谢舫*,胡凌云*,李臻博*,金博*,多功能多肽/脂质体/透明质酸组装的类病毒核酸载体,中国,授权号:CN105018529B。
(9) 杜子秀,彭佳惠,徐宇虹,王红霞,一种抗体连接载药纳米颗粒的抗体-纳米颗粒复合物,中国,授权号:CN201811054658。

未授权发明专利

(1) 杜子秀,陈娟,徐宇虹,韩士永,徐岩红,竺剑峰,一种抗体、多肽和核酸组合治疗靶向载体及制法和用途,中国,申请号:CN201811145326。
(2) 杜子秀,徐宇虹,梁瑶瑶,马丹婧,王红霞,一类具有双靶向功能的核酸输送纳米体系,中国,申请号:CN106362163A。
(3) 徐宇虹,王淑楠,吴飞,杜子秀,一种包载抗体-多糖颗粒的可注射PLGA原位凝胶的制备方法和应用,中国,申请号:CN201810113565。
© 2018 上海交通大学药学院

上海交通大学药学院
地址:上海市东川路800号
邮编:200240